Louisiana Medicaid Preferred Drug List (PDL) & NonPreferred Drug List (NPDL)

The Louisiana Medicaid program uses a tiered formulary system to help manage prescription drug costs while ensuring that beneficiaries receive safe and effective therapies. The core components of that system are the Preferred Drug List (PDL) and the NonPreferred Drug List (NPDL). Understanding how each list works, why drugs are placed on one list or the other, and what the implications are for patients, prescribers, and pharmacies can reduce administrative headaches and improve access to needed medication.

What Is the Preferred Drug List (PDL)?

The PDL is a catalog of drugs that the Louisiana Medicaid agency has determined to be the most costeffective options for a particular therapeutic class. Drugs on the PDL meet three primary criteria:

• Clinical efficacy: They have demonstrated comparable or superior outcomes to alternative therapies.
• Safety profile: They are considered safe for the broad Medicaid population, including vulnerable groups such as pregnant women, children, and the elderly.
• Costeffectiveness: They are priced lower than nonpreferred alternatives, often because of negotiated discounts, rebates, or the availability of generic versions.

When a medication is classified as preferred, Medicaid generally pays a larger portion of the cost (often up to 80% of the drugs allowable amount) and the patients copayment is lower. In many cases, prescribers are encouraged to start therapy with a PDL drug before considering other options.

What Is the NonPreferred Drug List (NPDL)?

The NPDL contains drugs that are either newer, have limited evidence for comparative effectiveness, or are priced significantly higher than their preferred counterparts. While these medications are still covered by Medicaid, they are subject to stricter utilization controls, such as higher copayments, priorauthorization requirements, or steptherapy protocols.

Key points about the NPDL:

• Higher patient costshare: Beneficiaries often pay a larger portion of the drug price, which can be a barrier for lowincome families.
• Prior authorization (PA): Prescribers must obtain approval from the Medicaid Pharmacy Benefits Management (PBM) before the drug can be dispensed.
• Step therapy: In many cases, patients must first try a preferred drug; only if the preferred option fails or is contraindicated can the prescriber move to a nonpreferred medication.

Why Do Drugs Move Between Lists?

The PDL and NPDL are not static. Quarterly and annual reviews by the Louisiana Department of Health (LDH) consider new clinical evidence, changes in drug pricing, and manufacturer rebates. When a nonpreferred drug demonstrates superior efficacy or becomes competitively priced, it may be added to the PDL. Conversely, a drug on the PDL may be moved to the NPDL if safety concerns arise or cheaper alternatives become available.

Manufacturers can also influence list placement. By offering additional rebates or participating in discount programs, a drug can become a more attractive option for the Medicaid program, leading to its inclusion on the PDL.

How the Lists Affect Different Stakeholders

Patients

Patients benefit from the PDL through lower outofpocket costs and fewer administrative hurdles. However, if a provider prescribes a nonpreferred drug, the patient may face higher copayments or delays while a priorauthorization request is processed. Education about the formulary helps patients understand why certain medications are preferred and how to navigate the system if they need a nonpreferred drug.

Prescribers

Clinicians should integrate the formulary into their prescribing workflow. Most electronic health record (EHR) systems now include realtime formulary checks that flag nonpreferred drugs and suggest preferred alternatives. For cases where a nonpreferred drug is truly indicated, the prescriber must submit a PA with supporting documentation (e.g., a documented allergy to a preferred drug, failure of steptherapy trials, or a specific clinical indication).

Pharmacies

Pharmacies receive realtime adjudication data from the Medicaid PBM. When a claim is submitted for a nonpreferred drug, the system may automatically generate a PA request, or the pharmacist may need to contact the prescriber for clarification. Prompt communication between pharmacist and prescriber can reduce claim rejections and ensure patients receive their medication without unnecessary delays.

Key Formularies and Resources

Common Scenarios and How to Handle Them

• Scenario 1 Patient needs a brandname drug that is not on the PDL. Start with a generic if available. If the brandname is medically necessary (e.g., specific formulation, lack of bioequivalence), the prescriber must submit a PA with justification.
• Scenario 2 Prior authorization is denied. Review the denial reason, correct any missing documentation, and appeal within the allowed timeframe (usually 30 days). Providers can also contact the PBMs clinical staff for clarification.
• Scenario 3 Pharmacist discovers a steptherapy requirement. The pharmacist should notify the prescriber, who can either confirm that steptherapy has been tried or provide a clinical rationale for bypassing it.

Best Practices for Navigating the PDL/NPDL System

• Stay current: The formulary changes frequently. Subscribe to LDH updates or set a calendar reminder for quarterly review releases.
• Use EHR formulary tools: Most systems will highlight preferred drugs and alert you when a nonpreferred medication is entered.
• Document thoroughly: For any PA, include diagnosis codes, priortherapy failures, and relevant lab results. This speeds approval and reduces the likelihood of a denial.
• Educate patients: Explain the reason for a preferred medication, the cost difference, and what steps are needed if a nonpreferred drug is required.
• Collaborate with pharmacists: They can assist with formulary checks, suggest therapeutic alternatives, and help navigate PA processes.

Conclusion

The Louisiana Medicaid Preferred Drug List (PDL) and NonPreferred Drug List (NPDL) are vital tools for controlling drug costs while maintaining therapeutic quality. By recognizing the criteria that determine a drugs placement, being aware of the financial and administrative implications for patients and providers, and employing bestpractice strategies for formulary navigation, stakeholders can minimize disruptions and promote better health outcomes. Keeping up to date with LDH releases, leveraging technology, and maintaining open lines of communication among prescribers, pharmacists, and patients are the cornerstones of a smooth Medicaid pharmacy experience.